ArticlePharmaceuticals (Basel, Switzerland)2020
Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities.
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 74 citations in OpenAlex.
- Electrospun Polyvinyl Alcohol/Polyethylene Oxide Loaded With Cisplatin as a Potential Candidate for Anticancer and Antibacterial Drugs.Chemistry & biodiversity · 2026Article
- Exploring the anti-diabetic properties of camel milk: effects on blood glucose, antioxidant defense, and organ histo-morphological features in rabbits.Journal of molecular histology · 2025Article
- Synthesis of F127-GA@ZnO nanogel as a cisplatin drug delivery pH-sensitive system.RSC advances · 2024Article
- Formulation development, characterization, and evaluation of sorafenib-loaded PLGA-chitosan nanoparticles.Frontiers in pharmacology · 2024Article
- The ameliorative effects of Alpinia officinarum rhizome hydroalcoholic extract on cisplatin-induced testicular toxicity in rats.JBRA assisted reproduction · 2023Article
- Anticancer Analysis of CD44 Targeted Cyclosporine Loaded Thiolated Chitosan Nanoformulations for Sustained Release in Triple-Negative Breast Cancer.International journal of nanomedicine · 2023Article
- Formulation for the Targeted Delivery of a Vaccine Strain of Oncolytic Measles Virus (OMV) in Hyaluronic Acid Coated Thiolated Chitosan as a Green Nanoformulation for the Treatment of Prostate Cancer: A Viro-Immunotherapeutic Approach.International journal of nanomedicine · 2023Article
- Supercritical Fluids and Nanoparticles in Cancer Therapy.Micromachines · 2022Review
- Enhancing the efficacy of albendazole for liver cancer treatment using mesoporous silica nanoparticles: anEXCLI journal · 2022Article
- PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells.Pharmaceutics · 2021Article
- The Nanosystems Involved in Treating Lung Cancer.Life (Basel, Switzerland) · 2021Review
- Anthelmintics for drug repurposing: Opportunities and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Review
- Camel milk as an alternative treatment regimen for diabetes therapy.Food science & nutrition · 2021Article
- Article
- Development and Optimization of Lipid-polymer Hybrid Nanoparticles Containing Melphalan Using Central Composite Design and Its Effect on Ovarian Cancer Cell Lines.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.Journal of experimental pharmacology · 2021Review
- In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.